Iwona Radziejewska
Overview
Explore the profile of Iwona Radziejewska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Czerwinska K, Radziejewska I
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519255
Gastrointestinal cancers are still the leading cause of death worldwide. This is related, among other things, to the non-specific symptoms, especially in the initial stages, and also to the limited...
2.
Radziejewska I
Biomed Pharmacother
. 2024 Apr;
174:116619.
PMID: 38643541
Glycosylation of cancerous epithelial MUC1 protein is specifically altered in comparison to that which is presented by healthy cells. One of such changes is appearing tumor-associated carbohydrate antigens (TACAs) which...
3.
Galicka A, Szoka L, Radziejewska I, Marcinkiewicz C
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835499
Integrins play a fundamental role in the migration and invasiveness of glioblastoma (GBM) cells, making them suitable targets for innovative cancer therapy. The aim of this study was to evaluate...
4.
Radziejewska I, Supruniuk K, Jakimiuk K, Tomczyk M, Bielawska A, Galicka A
Int J Mol Sci
. 2023 Sep;
24(17).
PMID: 37685842
Specific changes in mucin-type O-glycosylation are common for many cancers, including gastric ones. The most typical alterations include incomplete synthesis of glycan structures, enhanced expression of truncated O-glycans (Tn, T...
5.
Radziejewska I
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345016
Aberrant glycosylation of cell surface proteins is a very common feature of many cancers. One of the glycoproteins, which undergoes specific alterations in the glycosylation of tumor cells is epithelial...
6.
Radziejewska I, Supruniuk K, Tomczyk M, Izdebska W, Borzym-Kluczyk M, Bielawska A, et al.
Int J Mol Sci
. 2022 Aug;
23(15).
PMID: 35955735
Abnormal glycosylation of cancer cells is considered a key factor of carcinogenesis related to growth, proliferation, migration and invasion of tumor cells. Many plant-based polyphenolic compounds reveal potential anti-cancer properties...
7.
Supruniuk K, Czarnomysy R, Muszynska A, Radziejewska I
Transl Oncol
. 2022 Feb;
18:101348.
PMID: 35121220
The membrane-bound MUC1 mucin is overexpressed and aberrantly glycosylated in many epithelium origin cancers. One of the promising strategies in cancer therapy is combining monoclonal antibodies against cancer related antigens,...
8.
Radziejewska I, Supruniuk K, Czarnomysy R, Buzun K, Bielawska A
Pharmaceuticals (Basel)
. 2021 Oct;
14(10).
PMID: 34681197
Afzelin demonstrates anti-inflammatory and anti-cancer properties. Our purpose was to assess its influence on apoptosis, Bax, caspases, MUC1, cancer-related carbohydrate antigens, enzymes participating in their formation, and galectin-3 in AGS...
9.
Supruniuk K, Radziejewska I
Int J Oncol
. 2021 Jul;
59(3).
PMID: 34278474
Mucin 1 (MUC1) is a membrane‑bound, highly glycosylated protein that is overexpressed in all stages of malignant transformation. Overexpression of MUC1 together with loss of polarization and hypoglycosylation are associated...
10.
Supruniuk K, Czarnomysy R, Muszynska A, Radziejewska I
Pharmaceutics
. 2021 Jul;
13(7).
PMID: 34206951
MUC1 mucin is a transmembrane glycoprotein aberrantly overexpressed and underglycosylated in most epithelium origin cancers. Combining chemotherapeutics with monoclonal antibodies toward cancer-related antigens is one of the new strategies in...